Agilent Technologies, Inc.

Agilent Technologies, Inc. (A) Market Cap

Agilent Technologies, Inc. has a market capitalization of $33.88B.

Financials based on reported quarter end 2026-01-31

Price: $119.77

-0.62 (-0.51%)

Market Cap: 33.88B

NYSE · time unavailable

CEO: Padraig McDonnell

Sector: Healthcare

Industry: Medical - Diagnostics & Research

IPO Date: 1999-11-18

Website: https://www.agilent.com

Agilent Technologies, Inc. (A) - Company Information

Market Cap: 33.88B · Sector: Healthcare

Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The Life Sciences and Applied Markets segment offers liquid chromatography systems and components; liquid chromatography mass spectrometry systems; gas chromatography systems and components; gas chromatography mass spectrometry systems; inductively coupled plasma mass spectrometry instruments; atomic absorption instruments; microwave plasma-atomic emission spectrometry instruments; inductively coupled plasma optical emission spectrometry instruments; raman spectroscopy; cell analysis plate based assays; flow cytometer; real-time cell analyzer; cell imaging systems; microplate reader; laboratory software; information management and analytics; laboratory automation and robotic systems; dissolution testing; vacuum pumps, and measurement technologies. The Diagnostics and Genomics segment provides arrays for DNA mutation detection, genotyping, gene copy number determination, identification of gene rearrangements, DNA methylation profiling, gene expression profiling, next generation sequencing, target enrichment and genetic data management, and interpretation support software; and produces synthesized oligonucleotide. It also offers immunohistochemistry in situ hybridization, and hematoxylin and eosin staining and special staining; consumables, and software for quality control analysis of nucleic acid samples; and reagents for use in turbidimetry and flow cytometry, as well as develops liquid-based pharmacodiagnostics. The Agilent CrossLab segment provides GC and LC columns, sample preparation products, custom chemistries, and laboratory instrument supplies; and startup, operational, training, compliance support, software as a service, asset management, and consultation services. The company markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

Analyst Sentiment

75%
Strong Buy

Based on 38 ratings

Analyst 1Y Forecast: $163.22

Average target (based on 4 sources)

Consensus Price Target

Low

$140

Median

$168

High

$180

Average

$166

Potential Upside: 38.6%

Price & Moving Averages

Loading chart...

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 Agilent Technologies, Inc. (A) — Investment Overview

🧩 Business Model Overview

Agilent Technologies is a leading global provider of analytical instrumentation, software, consumables, and services for a wide range of life sciences, diagnostics, and applied chemical markets. The company’s core offerings enable laboratories across pharmaceutical, biotechnology, environmental, food safety, forensics, and academic research sectors to conduct precise chemical analysis, diagnostics, and measurement. Agilent serves enterprise clients—including commercial labs, healthcare providers, governments, and universities—delivering highly specialized solutions designed to meet rigorous scientific and regulatory standards. Its business operations span hardware development, digital workflow integration, laboratory automation, and ongoing support, positioning the company as a trusted partner throughout the analytical lifecycle.

💰 Revenue Model & Ecosystem

Agilent’s revenue model is anchored in a multi-pronged approach that combines recurring and transactional streams. Core revenues arise from the sale of sophisticated laboratory instruments such as liquid and gas chromatographs, mass spectrometers, and genomic analysis platforms. These high-value instruments form the foundation of long-term customer relationships and drive downstream demand for complementary products and services. Recurring revenues are generated through the sale of consumables (chemicals, columns, reagents), maintenance and support services, and increasingly, digital solutions including software subscriptions that power data analysis and laboratory workflow management. This ecosystem-oriented approach extends the economic life of hardware sales while promoting repeat engagement from enterprise customers.

🧠 Competitive Advantages

  • Brand strength: Agilent is recognized for its precision, reliability, and innovation, commanding a premium reputation in regulated scientific markets.
  • Switching costs: Laboratories invest significantly in Agilent platforms, with extensive operator training, integrated workflows, and validation making transitions to competitors challenging and costly.
  • Ecosystem stickiness: A comprehensive suite of cloud-based software, dedicated consumables, and service contracts fosters deep customer integration and multi-year engagement.
  • Scale + supply chain leverage: Agilent’s global footprint and manufacturing scale enable competitive pricing, rapid innovation cycles, and resilient supply for critical laboratory inputs.

🚀 Growth Drivers Ahead

Several secular trends and strategic initiatives position Agilent for sustained growth. Expansion in pharmaceutical R&D, particularly in biologics and precision medicine, is driving increased demand for advanced analytical and diagnostic solutions. Regulatory changes and heightened attention to food, environmental, and pharmaceutical safety are bolstering laboratory testing requirements worldwide. Agilent’s ongoing innovation in genomic analysis and its ability to integrate digital informatics into scientific workflows create opportunities for growth in both existing and adjacent markets. Strategic investments in emerging economies, selective acquisitions, and partnerships are broadening Agilent’s customer base and deepening its penetration into high-growth end markets. The company’s emphasis on recurring revenue streams, digital transformation, and customer-centric service further enhances long-term prospects.

⚠ Risk Factors to Monitor

Key risks for Agilent include intensifying competition from global and niche analytical instrument providers, which may compress margins or necessitate greater R&D spending. Regulatory environments can be complex and subject to change, potentially impacting product development cycles or market access. Given the high value of its offerings, capital spending constraints on the part of large customers during economic downturns could reduce demand. Furthermore, rapid technological advances—such as new forms of automation or disruptive data analytics—pose the risk of incumbent platforms being superseded. Supply chain disruptions, currency fluctuations, and geopolitical uncertainties also warrant close monitoring due to Agilent’s international exposure.

📊 Valuation Perspective

Agilent is typically valued by the market at a premium relative to many traditional industrial and instrumentation peers, reflecting its exposure to secular growth industries, sticky recurring revenue models, and leadership in high-margin scientific domains. Investors often price in a higher growth and quality profile, particularly when compared to companies concentrated in more cyclical or less regulated markets. However, this premium is subject to fluctuations depending on the pace of organic growth, the proportion of recurring revenues, and the broader sentiment toward the life sciences and healthcare technology sectors.

🔍 Investment Takeaway

Agilent Technologies stands out as a high-quality operator in critical laboratory and analytical domains, benefiting from strong brand equity, entrenched customer relationships, and a defensible ecosystem. The company’s focus on recurring revenue expansion, automation, and digital solutions position it well for enduring demand in dynamic end markets. While high competitive intensity, regulatory complexity, and innovation cycles pose real risks, Agilent’s scale and innovation culture provide a buffer against disruption. For investors, the core thesis hinges on sustained secular growth and operational excellence balanced against a valuation that presumes continued execution. Overall, Agilent remains an attractive long-term idea for portfolios seeking exposure to life sciences technology and defensive growth, provided risks and market expectations are well understood.


⚠ AI-generated research summary — not financial advice. Validate using official filings & independent analysis.

Agilent delivered a solid Q1 within guidance despite a weather-related shipment disruption and ongoing tariff headwinds. Growth was led by pharma, semiconductors, and diagnostics, with strong momentum in GLP-1 workflows, LC/MS, and services. Margins were pressured by tariffs but are expected to improve sequentially as volumes rise and Ignite efficiencies accrue. Management maintained FY26 core growth and margin expansion targets and modestly raised EPS guidance on FX, while flagging softness in academia/government and tariff uncertainty. Overall tone was constructive with disciplined execution and stable outlook.

Growth

  • Core revenue +4.4% YoY; reported +7% (FX tailwind +2.6%)
  • ACG +6%; AMG +4%; LDG +3% (below expectations)
  • Pharma +7% (biotech double-digit; small molecule mid-single-digit)
  • Chemicals & Advanced Materials +9% (advanced materials >20%)
  • Diagnostics & Clinical +7%; Environmental flat; Food -4% (ex-China low double-digit growth); Academia & Government -8%
  • GLP-1-related revenue +50%; Specialty CDMO low double-digit in Q1 (FY26 mid-teens expected)
  • LC instruments high single-digit; GC low single-digit (ex-China mid-single-digit)
  • Single-quad LC/MS family >40% growth
  • Geography: China +6%; Rest of Asia +13%; Europe +4%; Americas +1% (weather impact)
  • Instrument book-to-bill at or above 1 for 8 consecutive quarters

Business Development

  • Enterprise Services wins with major pharma; now ~10% of services revenue; low double-digit CAGR; agreements with nearly all top 20 biopharma; 18 competitive displacements over 3 years
  • CrossLab Connect digital monitoring/analytics deepening customer intimacy and wallet share
  • Altura columns launched for biopharma (GLP-1) and PFAS workflows; biocolumn growth >30%; PFAS columns address EU regs and double throughput
  • Pro iQ LC/MS gaining traction; Omnis platform expanded to medium-throughput labs; S-540-MD Slide Scanner launched
  • Raman Insight BRT security system secured $9M TSA contract; positioned for larger aviation tenders
  • Successful BIOVECTRA integration demonstrating repeatable M&A playbook

Financials

  • Revenue $1.8B; EPS (non-GAAP) $1.36
  • Operating margin 24.6% (down 50 bps YoY); gross margin 53.7% (down 100 bps YoY) primarily from tariffs and normalized performance-based pay
  • Weather disruption (U.S. storm) impacted revenue by ~$10M; majority recovered in early February; adjusted results would have been above midpoints of guidance
  • Other income $10M; tax rate 14.5%; diluted shares ~283M
  • Operating cash flow $268M; capex $93M
  • FY26 guide: revenue $7.3–$7.5B (core +4% to +6%; FX +1.5% tailwind); EPS $5.90–$6.04 (raised $0.04 on FX)
  • Q2 guide: core growth ~4%–5.5% (includes most storm recovery); EPS $1.39–$1.42 (~+7% YoY midpoint)
  • Expect sequential margin improvement in FY26 from volume leverage, easing tariffs, and Ignite benefits; targeting ~+75 bps FY26 operating margin expansion at midpoint

Capital & Funding

  • Share repurchases $152M in Q1; dividends paid $72M
  • Net leverage ~0.8x; balance sheet remains strong
  • Continued investment in innovation and capacity expansion; disciplined M&A focus
  • Capex $93M in Q1

Operations & Strategy

  • Ignite Operating System driving execution, faster decisions, and enterprise alignment
  • Ignite achievements: doubled pricing realization, substantial procurement savings, tariff mitigation, org simplification, successful BIOVECTRA integration, new agilent.com (digital orders >2x overall order book growth)
  • New Ignite workstreams: speed-to-market, enhanced digital/e-commerce, targeted AI for customer insights/automation/manufacturing cycle-time reduction, accelerated software development, supply chain resilience and localization
  • Commercial focus on LC/GC replacement cycles, GLP-1 workflows, and semiconductor atomic spectroscopy leadership

Market & Outlook

  • Market conditions generally improving and consistent with expectations
  • Secular drivers: pharma and semiconductor reshoring, GLP-1 uptake, LC/GC replacement cycles
  • Pharma reshoring in U.S. estimated ~$1B TAM through 2030; first orders expected late FY26; revenue impact from FY27 onward
  • Diagnostics & Clinical supported by Omnis; Environmental & Forensics low single-digit FY growth expected; Food flat FY; Academia & Government low single-digit decline FY
  • Europe slowed late in quarter due to tariff discussions; tariff headwinds expected to decrease through the year

Risks Or Headwinds

  • Tariff headwinds compressing gross margin; policy outlook remains fluid
  • Weather/logistics disruptions (e.g., U.S. winter storm) can impact shipments
  • Softness in Academia & Government spending, particularly in the U.S.
  • European customer purchasing delays tied to tariff uncertainty
  • China comps (especially in Food) create uneven demand
  • Normalized performance-based pay weighing on margins YoY

Sentiment: MIXED

Note: This summary was synthesized by AI from the A Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Fundamentals Overview

Loading fundamentals overview...

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-01-31

"Company A reported quarterly revenue of $1.798 billion, net income of $305 million, and EPS of $1.08. The net margin stands at approximately 16.95%. The company generated robust free cash flow of $268 million, thanks to efficient operations with no capital expenditures this quarter. Year-over-year revenue growth details are unavailable, but the operating cash flow suggests effective business efficiency. Profitability remained strong with the healthy net margin and EPS growth. The operating cash flow fully converted into free cash flow, showcasing the company's capacity to generate cash without capital expenditures. Cash reserves have grown to $1.76 billion, with net debt reasonably managed at $1.596 billion. Shareholder returns included $72 million in dividends and $152 million in stock repurchases, signaling management's commitment to returning value to investors. The balance sheet is strong, with a debt/equity ratio of 0.23, reflecting prudent financial management. Analyst sentiment is positive with a consensus price target of $166.36, suggesting valued growth potential. Overall, Company A demonstrates robust fundamentals with effective capital allocation strategies, yet sustained growth relies on potential revenue expansion and market conditions."

Revenue Growth

Positive

Revenue growth metrics are unspecified, yet consistent operating cash flow implies stable business operations.

Profitability

Strong

Net margin of 16.95% and EPS of $1.08 indicate strong profitability and efficient operations.

Cash Flow Quality

Good

Free cash flow stability is evident with no capital expenditure and comprehensive shareholder returns.

Leverage & Balance Sheet

Good

Net debt at $1.596 billion is manageable, supported by $1.76 billion in cash and a solid debt/equity ratio of 0.23.

Shareholder Returns

Good

Robust returns with $72 million in dividends and $152 million in buybacks, demonstrating a commitment to shareholders.

Analyst Sentiment & Valuation

Good

Positive analyst sentiment with a consensus target implying potential growth; valuation appears aligned with market expectations.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Loading financial data and tables...
📁

SEC Filings (A)

© 2026 Stock Market Info — Agilent Technologies, Inc. (A) Financial Profile